- $3 Billion Annual Cost Savings Initiative by End of 2027
Merck announced a major multiyear optimization and restructuring plan aimed at generating $3 billion in annual cost savings by 2027. This initiative includes eliminating administrative, sales, and R&D positions, reducing its global real estate footprint, and optimizing its manufacturing network. The company expects cumulative pre-tax costs of about $3 billion related to this program, with charges of $649 million recorded in Q2 2025 alone. The annual savings of roughly $1.7 billion will be substantially realized by the end of 2027 and fully reinvested to support new product launches and its pipeline across multiple therapeutic areas. - Strategic Shift to Reallocate Resources Toward Growth Drivers
Merck’s CEO Robert M. Davis views this restructuring as a “reallocation” rather than a cut, intending to redirect funds away from slower growth areas toward high-potential new products. This reallocation supports over 20 upcoming product launches, including ongoing Phase III trials and commercialization efforts. Investments will continue in U.S. manufacturing and R&D, including a $1 billion biologics center of excellence in Delaware to produce Keytruda and an $895 million expansion of its Animal Health manufacturing facility in Kansas. - Impact on Product Portfolio and Pipeline
Merck aims to bolster its pipeline in oncology, respiratory, and other therapeutic areas. Notably, the company completed the pending acquisition of Verona Pharma for $10 billion, adding a novel cardiopulmonary product “Ohtuvayre” (approved for COPD maintenance treatment) to its offerings. Keytruda remains a priority as Merck prepares for patent expiry and increasing competition, continuing clinical trials for additional indications and a subcutaneous version. - Financial Results and Market Outlook
In Q2 2025, Merck reported $15.8 billion in revenue, slightly below expectations, with GAAP EPS at $1.76 and non-GAAP EPS at $2.13. The company narrowed its 2025 sales guidance to $64.3-$65.3 billion and non-GAAP EPS guidance to $8.87-$8.97, excluding the anticipated impact of Verona Pharma acquisition closing. Cost reductions target a leaner, more efficient structure to sustain R&D growth and maintain competitiveness amid shifting market dynamics.
About Merck
Merck & Co., Inc. (MSD outside US & Canada) is a global biopharmaceutical company dedicated to innovating therapies across oncology, vaccines, cardio-pulmonary, and infectious diseases. Known globally for medicines like Keytruda and Gardasil, Merck invests strategically in science and infrastructure to advance healthcare solutions that improve patient outcomes worldwide.
By
